Abstract:
THE EXPERIMENT AND PRIMARY CLINICAL PRACTICE OF 90Y,32PGTMS INTERVENING TREATMENT OF MALIGNANT TUMOUR Gao Kejia (Department of Nuclear Medicine,Shanghai Central Hospital of Huangpu District,200002) Zhu Ruisen Yuan Zhibin Zhu Jifang Ma Jixiao (Department of Nuclear Medicine, Shanghai Central of the Sixth Hospital,200233) ABSTRACT 90YGTMS and 32PGTMS is injected directly into the carcinoma mass to kill the cancerous cells, prevent the tumour from growing and prolong the life of the malignant tumour patients. In the tumour body of the Dutch rat model, the contrast group,the cryogen group and the differential dose group (90YGTMS divided into 92.5,185,370 MBq,32PGTMS divided into 37,92.5,185 MBq) are observed the curative effect at the different time.The effective dose of the nuclide per unit voume is gotten to be used in clinical practice. With the help of Bultrasonography, the tumour is located and then directly injected 90YGRMS with puncture. 32PGTMS is embedded directly into the tumour during the operation and then the change of the tumour size is observed. With the proof of animal experiment, when the volume of the tumour is (0.262±0.050)cm3, the amount of 90YGRMS>185 MBq or 32P GTMS>92.5 MBq is used as effective dose. The longer time the nuclide is embedded in the tumour, the more obvious the curative effect is. In the clinical practice, leading by the Bultrasonography, 16 liver cancer patients receive the 90YGRMS with punctura and 6 patients received the 32PGTMS treatment in some part of the tumour during the operation. Their Bulatrasonography and CT development shows that 97% of the mass has becomes smaller or doesn′t become larger any more, and the pathology displays that the cell has narcotized. 90YGTMS,32PGTMS intervening treatment can provide an effective palliative treatment to those tumour patients, who have lost the chance of surgical operation. Key words 90Yglass atomic spherule (90YGTMS) 32Pglass atomic spherule(32P GTMS) intervening treatment observation of curative effect